Angelica Ballesteros
2 min read
In This Article:
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the Massive Sell-Offs: These 10 Stocks Shockingly Nosedived.
ADMA Biologics fell by 14.7 percent week-on-week, closing Friday at $17.74 versus the $20.81 on June 13, as investors took path from three of its executives’ recent disposition of shares in the company.
In a regulatory filing, ADMA Biologics, Inc. (NASDAQ:ADMA) President and CEO Adam Grossman sold 21,000 ADMA shares at a price of $20.81 apiece on June 16 for a total value of $437,010. On the same day, he acquired 15,000 shares at a price of $5.4 apiece for a total of $81,000.
ADMA Biologics, Inc. (NASDAQ:ADMA) said that the transaction was in line with the Rule 10b5-1 trading plan entered into between Grossman and Fidelity Brokerage Services LLC.
The transaction followed sales activities made by the company’s chairman, Steven Elms, and founder and vice chairman, Jerrold Grossman.
For his part, Elms sold 425,621 of his shares in the company for an aggregate market value of $9.3 million, while Jerrold disposed of 10,000 shares at an aggregate market value of $206,100.
An independent distributor in their pharmacy with a range of biopharmaceutical products on display.
It is worth noting that ADMA Biologics, Inc.’s (NASDAQ:ADMA) closing price on Friday marked its sixth straight day of decline.
While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
